骶神经调节治疗膀胱过度活动症的前瞻性多中心研究五年随访结果
该前瞻性多中心研究评估了骶神经调节(InterStim™)植入5年后的治疗成功率、生活质量变化和安全性。340例完成测试刺激的膀胱过度活动症受试者中272例接受植入,5年治疗成功率为67%(改良完成者分析,95%CI 60-74)和82%(完成者分析,95%CI 76-88),生活质量各维度均改善,安全性可接受。
要点
- 5年治疗成功率:改良完成者分析67%(95%CI 60-74),完成者分析82%(95%CI 76-88)。
- 尿急尿失禁者漏尿日均减少2.0±2.2次,尿频尿急者排尿日均减少5.4±4.3次(各完成者分析p<0.0001)。
- 最常见器械相关不良事件:刺激变化60/272例(22%)、植入部位疼痛40例(15%)、产品无效36例(13%)。
核心结论
- 该多中心研究显示,骶神经调节在膀胱过度活动症受试者中至5年具有持续疗效和生活质量改善,安全性可接受。
研究设计与样本
- 前瞻性多中心研究,纳入膀胱过度活动症伴尿急尿失禁和/或尿频尿急、至少1种抗胆碱能药物失败且1种药物未尝试的受试者。
- 340例受试者完成测试刺激,其中272例接受InterStim™植入,91%为女性,平均年龄57岁。
- 治疗成功定义为尿急尿失禁或尿频尿急应答达到日均漏尿或排尿改善50%或以上,或恢复正常排尿(每日排尿少于8次)。
- 生活质量采用ICIQ-OABqol(国际尿失禁咨询委员会模块化问卷)评估,安全性通过不良事件评估。
主要发现
- 基线时202例尿急尿失禁受试者日均漏尿3.1±2.7次,189例尿频尿急受试者日均排尿12.6±4.5次。
- 5年治疗成功率:改良完成者分析67%(95%CI 60-74),完成者分析82%(95%CI 76-88)。
- 尿急尿失禁受试者日均漏尿较基线平均减少2.0±2.2次,尿频尿急受试者日均排尿平均减少5.4±4.3次(各完成者分析p<0.0001)。
- 受试者所有ICIQ-OABqol指标均显示改善(p<0.0001)。
- 最常见器械相关不良事件:刺激变化60/272例(22%)、植入部位疼痛40例(15%)、治疗产品无效36例(13%)。
关键数值与推荐
- 治疗成功定义:尿急尿失禁或尿频尿急应答达到日均漏尿或排尿改善50%或以上,或恢复正常排尿(每日排尿少于8次)。
- 5年治疗成功率:改良完成者分析67%(95%CI 60-74),完成者分析82%(95%CI 76-88)。
- 尿急尿失禁受试者日均漏尿较基线平均减少2.0±2.2次(完成者分析p<0.0001)。
- 尿频尿急受试者日均排尿较基线平均减少5.4±4.3次(完成者分析p<0.0001)。
- 所有ICIQ-OABqol指标改善(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the therapeutic success rate, changes in quality of life and safety of sacral neuromodulation 5 years after InterStim™ implantation. Included in study were subjects with bothersome symptoms of overactive bladder, including urinary urge incontinence and/or urgency-frequency, in whom at least 1 anticholinergic medication failed and 1 medication had not been tried. MATERIALS AND METHODS: Therapeutic success was defined as a urinary urge incontinence or urgency-frequency response of 50% or greater improvement in average leaks or voids per day, or return to normal voiding, defined as fewer than 8 voids per day. Quality of life was evaluated by ICIQ-OABqol (International Consultation on Incontinence Modular Questionnaire). Safety was evaluated through adverse events. RESULTS: Of the 340 subjects who completed the test stimulation 272 had an implant, of whom 91% were female. Mean age was 57 years. At baseline 202 subjects with urinary urge incontinence had a mean ± SD of 3.1 ± 2.7 leaks per day and 189 with urgency-frequency had a mean of 12.6 ± 4.5 voids per day. The 5-year therapeutic success rate was 67% (95% CI 60-74) using modified completers analysis and 82% (95% CI 76-88) using completers analysis. Subjects with urinary urge incontinence had a mean reduction from baseline of 2.0 ± 2.2 leaks per day and subjects with urgency-frequency had a mean reduction of 5.4 ± 4.3 voids per day (each completers analysis p <0.0001). Subjects showed improvement in all ICIQ-OABqol measures (p <0.0001). The most common device related adverse events were an undesirable change in stimulation in 60 of the 272 subjects (22%), implant site pain in 40 (15%) and therapeutic product ineffectiveness in 36 (13%). CONCLUSIONS: This multicenter study shows that sacral neuromodulation had sustained efficacy and quality of life improvements, and an acceptable safety profile through 5 years in subjects with overactive bladder.
引用
- Siegel S, Noblett K, Mangel J, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2017. PMID: 28709886. doi:10.1016/j.juro.2017.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。